BioCentury
ARTICLE | Company News

Alchemia, Cancer Research Technology deal

March 10, 2014 7:00 AM UTC

Alchemia licensed two preclinical focal adhesion kinase (FAK) inhibitors from Cancer Research Technology. Alchemia will evaluate the compounds in cancer and cancer stem cell models and potentially develop the compounds for undisclosed cancer indications. Cancer Research Technology will receive an upfront payment and is eligible for milestones and royalties. Cancer Research Technology declined to disclose details, and Alchemia could not be reached. ...